Handbook on Injectable Drugs
iOS Universel / Medecine
“Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content.
Based on 25th edition, for over 50 years American Society of Health-System Pharmacists is the most comprehensive reference on injectable drug data. 2025 edition features 400+ monographs on parenteral drugs, 24,500+ compatibility pairs, 3,700+ unique references
5-Star Rating from Doody's Review Service 2021,2022,2023,2024 Doody's Core Titles List Selection
For more than 50 years ASHP has published the most trusted resource for injectable drug information. Our new ASHP® Injectable Drug InformationTM now delivers the same high-quality content that you can expect from ASHP with even MORE of the information you need to make decisive patient care decisions.
ASHP® Injectable Drug InformationTM 2025 content is interactive, mobile, and updated quarterly. Includes monographs to Extended Stability for Parenteral Drugs, forming a single, comprehensive resource on injectable drug information.
Backed by quality, peer-reviewed published literature & authored under the editorial authority of ASHP, it is a must-have resource for every pharmacy. A Comprehensive Guide to IV Compatibility & Stability
The 2025 Edition of the industry’s go-to guide is newly updated with the latest information, ASHP’s Standardize 4 Safety (S4S) concentration standards including new Adult and Pediatric PCA and Epidural standard concentrations, and the full list of the AHFS® Pharmacologic-Therapeutic Classification© system.
Current 2025 edition features:
- More than 420 monographs
- 270+ new references
- Over 25,000 total compatibility pairs
- A Comprehensive Guide to IV Compatibility & Stability
Key Features
- Quick data search for 350+ drugs
- 400+ monographs on parenteral drugs available in USA & in other countries
- Monographs cross-referenced with American Society of Health-System Pharmacists (AHFS) Drug Information through AHFS classification numbers
- 500+ revisions to existing monographs (affecting nearly 60% of the existing monographs) have been accomplished to update information on stability, compatibility, safety (e.g. Food & Drug Administration [FDA] MedWatch alerts) & to provide more specific referencing of manufacturer information & other enhancements to the more than 24,100 compatibility pairs contained in ASHP® Injectable Drug Information™ 2025.
- How to prepare, store and administer drugs
- Information accumulated from 3,600+ references
- Quick identification of drug compatibility with easy to understand icons
- Drugs listed alphabetically by generic name for efficient searching, with brand names also listed
- Tabulated results from primary research on the compatibility of the listed drug with infusion solutions & other drugs
- Four compatibility tables are provided for each drug: solution, additive, syringe, Y-site
- Parenteral Drugs by Caryn Bing and Anna Nowobilski-Vasilios. This extended stability information is specifically designed for use in home and other infusion practices
Content licensed from printed edition ISBN 10: 1585287431 & ISBN 13: 9781585287437
SUBSCRIPTION :
Please purchase a yearly auto-renewing subscription to receive content access and available updates.
Yearly auto-renewing payments- $49.99
Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable.
Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx
Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx
Editor(s):ASHP
Publisher:American Society of Health-System Pharmacists
Quoi de neuf dans la dernière version ?
- ASHP® Injectable Drug Information™ 2025 includes 102 Total New and Revised Monographs
- NEW Monographs Crovalimab, Antithymocyte Globulin (Equine), Ravulizumab, Eculizumab
- While primary, peer-reviewed literature remains a major source of compatibility and stability information, ongoing efforts are underway to provide increased specificity of references to the pharmaceutics research of drug manufacturers. Other relevant information and pertinent study details supplied by corresponding authors of the published literature also have been incorporated when available.
